Fresenius Medical Care AG & Co. KGaA (ETR: FME)‘s stock had its “buy” rating restated by analysts at Bryan Garnier & Cie in a research report issued to clients and investors on Friday. They currently have a $87.33 (€66) price target on the stock.

Other equities research analysts have also recently issued reports about the stock. Analysts at AlphaValue reiterated an “add” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note to investors on Friday, February 8th. They now have a $77.73 price target on the stock. Finally, analysts at Sanford C. Bernstein reiterated an “outperform” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note to investors on Monday, January 28th. They now have a $83.11 price target on the stock.

Shares of Fresenius Medical Care AG & Co. KGaA traded up 0.33% during mid-day trading on Friday, hitting €52.44. Fresenius Medical Care AG & Co. KGaA has a one year low of €47.982 and a one year high of €60.24. The stock’s 50-day moving average is currently €56.72.

Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.